Compare Crispr Therapeutics AG (CRSP) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs JetBlue Airways Corporation — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while JetBlue Airways Corporation trades at $3.84 (market cap $1.48B). The key difference: Crispr Therapeutics AG is far larger — about 3.3× JetBlue Airways Corporation's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and JetBlue Airways Corporation for 44 Days on average.
| CRSP | JBLU | |
|---|---|---|
Market Cap | $4.88B | $1.48B |
Volume | 2,861,747 | 30,275,693 |
Sector | Health | Industrials |
52-Week High | $74.92 | $6.46 |
52-Week Low | $44.34 | $3.92 |
Typical Hold Time | 77 Days | 44 Days |
Enterprise Value | $3.30B | $8.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
JetBlue (JBLU) trades at $3.92, down 1.26% with a bearish technical outlook. The airline faces fundamental challenges with negative net income margins (-9.32%) and declining revenue trends, though valuation metrics like P/S (0.15) appear attractive. Recent developments include route expansion to Colombia and new first-class seating, but the company continues to struggle with profitability amid high fuel costs and competitive pressures.
Investment outlook remains cautious with significant execution risks. While analyst consensus suggests moderate upside to the $5.89 price target, persistent losses and high debt levels (debt-to-asset ratio over 50%) create headwinds. The stock offers speculative value for investors betting on operational turnaround, but requires careful risk management given the challenging industry environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
